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Melanoma is among the leading causes of cancer death in younger adults. 
Established risk factors are mostly nonmodifiable with the exception of exposure to 
ultraviolet radiation. Because melanomas are not limited to areas of the body that are 
exposed to ultraviolet radiation and because other risk factors do not account for many 
cases of melanoma, it is expected that there are yet unidentified risk factors. 
Overall, melanoma incidence rates continue to rise despite efforts to educate 
people about the risk of sun exposure and tanning beds. This increase combined with the 
aggressive and dangerous nature of melanoma in advanced stages has fueled campaigns 
for prevention and early diagnosis. When caught early, melanoma treatment is relatively 
successful when treated with surgery.  
The present study evaluates risk factors that have been suggested by previous 
research done primarily on non-U.S. populations. These include vitamin D levels, body 
mass index, and height. The databases in some European countries are extensive and have 
provided a platform to investigate these risk factors. The limitations of this thesis are few 
but important. Germaine to proving the necessity of this study is the limitation that the 
cohorts are very geographically narrow.  
The Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer cohort provides a 
large and geographically diverse U.S. population for this study. It enrolled and followed 
over 150,000 people for 13 years each to evaluate the efficacy of screening for each of 
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the 4 cancer types. Incidence of all other cancer types were also recorded but not studied 
as they are not the primary aims of the PLCO. 
In this review of the data provided by the PLCO, the following associations or 
lack thereof were found: 
High self-reported vitamin D intake seemed to predict an increased risk of 
melanoma among men but not women. There was no dose response curve or trend 
between reported vitamin D intake and melanoma risk. Serum vitamin D levels did not 
seem to predict disease severity as measured by tumor thickness.  
There was an interesting correlation between melanoma risk and body mass index 
(BMI) calculated from reported height and weight at age 20. In men, being underweight 
at age 20 seemed to be protective while in women being overweight at age 20 seemed to 
be protective. BMI did not correlate with disease severity as measured by tumor 
thickness. 
Height seemed to be correlated to melanoma risk. There was significant trend 
between increasing height and melanoma risk in men and women. Those in the highest 
quartile of height were at a significantly increased risk compared to those in the lowest 
quartile. 
In summary, this analysis of PLCO data confirms the difficulty of identifying risk 
factors for melanoma. We corroborated the finding that height is positively correlated 
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Melanoma is most commonly a cancer that originates in the skin. In 2016, it is 
expected that there will be more than 75,000 cases of melanoma and more than 10,000 
deaths in the US.1 The lifetime risk of melanoma continues to rise and may affect as 
many as 1 in 50 people in the US. It is currently accepted that the primary modifiable risk 
factor for melanoma is exposure to ultraviolet (UV) light. Knowledge of this risk factor 
has allowed public awareness campaigns to stem the tide of melanoma rates in 
Australia.2-4 While it is hoped that public awareness in the US will have a similar effect, 
the rates of melanoma continue to increase steadily.1 Other known risk factors for 
melanoma are not modifiable. They include lighter skin complexion, higher numbers of 
or clinically atypical nevi (moles), genetic predisposition, age, and gender. While altitude 
and latitude play into risk, they do so by modification of UV exposure.  
Understanding the risk factors of melanoma has proven beneficial in at least two 
ways. When possible, primary prevention through reduction of UV exposure has been 
proven in Australia.5 Secondary prevention (reduction of disease specific morbidity and 
mortality) has also been effective as evidenced by the steady mortality rate relative to the 
steady increase in incidence of melanoma in the US. The National Cancer Institute’s 
“Surveillance, Epidemiology and End Results Program” (SEER) shows that while 
melanoma rates are increasing in the US, 5-year disease-specific survival has increased 
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from 81% in 1975 to 93% in 2012.1 While there have been advances in melanoma 
therapies that started in 2010, 6 these data do not reflect those advances. It is likely that 
the improvement in rates is attributable to secondary prevention (ie, earlier diagnosis).  
Melanoma is an aggressive cancer due to the melanocyte’s embryonic origin in 
the neural crest. As melanocytes are derived from the neural crest, they have an ability to 
migrate through the body. The spread of melanoma (metastasis) requires tumor cells to 
penetrate deep into the dermal anatomy to access the vascular or lymphatic bundles that 
lie in the dermis. Thus, secondary prevention (ie, early diagnosis and treatment before 
metastasis occurs) is crucial. This also explains why the most important prognostic factor 
at diagnosis is the thickness of the tumor (also known as Breslow depth).7 
In an effort to further understand the risk factors of melanoma and potentially 
allow more focused efforts in primary and secondary prevention, this dissertation will 
evaluate low vitamin D levels, increased BMI, and increased height as potential risk 
factors of both incidence and severity of melanoma. The Prostate, Lung, Colorectal, and 
Ovarian Cancer Screening Trial data will be used for secondary data analysis to 
accomplish these aims. 
1.1 Vitamin D and Melanoma 
The benefits of adequate vitamin D levels are well known. However, it appears 
that low vitamin D levels may be relatively common. More than half of some racial 
minorities have been found to have low serum levels of vitamin D.8 The obvious 
consequences of low vitamin D include rickets and bone fragility. Adequate vitamin D 
levels have been shown to protect against some cancers9,10 and has been shown to reduce 
the severity of some chronic illnesses.11-14  
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With increasing evidence of the benefit of adequate levels of vitamin D, more 
efforts are being made to increase vitamin D levels. These efforts include dietary and 
behavioral interventions (increasing UV exposure). 15-17 Dietary sources of vitamin D are 
helpful, but in the absence of adequate dietary intake or supplementation, increased sun 
or UV exposure is required to increase vitamin D levels. The danger in this is the 
corresponding increased risk of skin cancer related to UV exposure. Wrapped up in this 
complex interaction of variables is the question of what influence vitamin D levels have 
on skin cancer and, in particular, melanoma risk and behavior. In this dissertation, we aim 
to evaluate the relationship of vitamin D intake and melanoma risk and Breslow thickness 
within the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer cohort. It is 
hypothesized that high vitamin D intake and high serum levels are correlated and 
protective against melanoma. Also, high vitamin D levels are hypothesized to be 
associated with a shallower Breslow thickness at the time of melanoma diagnosis 
1.2 BMI and Melanoma 
While there seems to be a reproducible increase in the risk of melanoma among 
males with high BMI,18,19 there is yet to be any physiologic explanation for this 
phenomenon. The largest study conducted in a U.S. population did not show an 
association between BMI and melanoma risk but only included women.20 A confirmatory 
study looking at BMI within a larger U.S. cohort of men and women is, therefore, 
warranted. Studies done outside the US that included men suggested a higher risk of 
melanoma among men in the highest groupings of BMI.19 Sergentanis et al found a 
similar increased risk among men who were overweight.18 A corresponding dose 
response or trend was not seen in these studies raising the question of unidentified effect 
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modifiers or confounders and raises doubt about the strength of evidence for this 
proposed association. 
1.3 Height and Melanoma 
Some studies suggest an unexplained increased risk of melanoma among men in 
higher categories of BMI. The lack of a physiologic explanation or a predictable linear 
relationship between BMI and melanoma suggests other factors may be at play. There 
have been a few studies that suggest height as a potential risk factor independent of 
weight.19,21-23 Moreover, there seems to be a linear relationship with increased risk of 
melanoma and increased height. One study, in particular, associated height with an 
increased nevus count.24 Studies of melanoma cell lines in vitro have revealed a high 
level of growth hormone receptors.25 Meyle et al found that increased childhood height 
was correlated with a higher risk of melanoma as an adult.21 When all of these factors are 
considered in the context of the evidence that UV exposure during childhood and teenage 
years is more damaging, one possibility may be that human growth factor influences 
melanocytes in a way that makes them more susceptible to UV damage.  
1.4 The Present Study 
The majority of studies evaluating these potential risk factors of melanoma have 
included large cohorts that are either demographically limited or not based in the US. The 
PLCO is of particular value given that it represents a larger U.S. cohort that is 
demographically and geographically diverse.  
The methods of the PLCO have been previously published in detail.26 It is a 
population-based randomized trial developed to evaluate the effect of screening for 
prostate, lung, colorectal, and ovarian cancers on cancer-specific mortality. The trial 
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included 10 screening centers across the US and enrolled 78,216 women and 76,685 men 
all between the ages of 55 and 74.  
Each participant completed a baseline and dietary questionnaire. The dietary 
questionnaire has been validated in three different studies.27-29 After meeting enrollment 
criteria, each participant was randomized into the intervention arm (receiving intervention 
screening for the targeted cancers) or the control arm (standard of care). Those in the 
intervention arm received PLCO cancer-specific screening for the first 6 years and were 
then followed for 7 additional years.  
Evaluating these risk factors (vitamin D, BMI, and height) using the data collected 
by the PLCO may shed new light on the topic and may strengthen or refute associations 
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The incidence rate of melanoma continues to increase despite public awareness 
campaigns. Other than limiting ultraviolet (UV) light exposure, a few factors are known 
to prevent or reduce severity of melanoma. Limiting UV exposure may cause vitamin D 
deficiency, a very prevalent condition with known detrimental health implications. This 
study aims to evaluate a potential relationship between vitamin D intake and melanoma 
risk within the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer cohort. 
2.1.2 Methods 
The PLCO followed more than 150,000 people for 13 years. Each participant’s 
health status was tracked and participants were asked to fill out multiple surveys 
including a food frequency questionnaire. Oral (both diet and supplemental) vitamin D 
intake was collected from this questionnaire. Health histories and demographic 
information were collected from each participant at the time of enrollment. A small 
subset of participants had serum vitamin D levels available as well. Over 1,300 PLCO 
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participants developed melanoma during the course of follow up. Both Cox and linear 
regressions were used to estimate the risk of melanoma and the association with tumor 
thickness.  
2.1.3 Results 
While not statistically significant, there was a suggestion of an increased risk of 
melanoma among men within the highest quartile of vitamin D intake (HR 1.27, 95% CI 
0.99, 1.61). Participants in the highest quartile of vitamin D intake who enrolled at low 
UV index centers may be at higher risk for melanoma than individuals who were in the 
high vitamin D intake quartile and enrolled at high UV centers (HR 1.24, 95% CI 0.99, 
1.56). When including only invasive melanoma, women in the highest quartile of vitamin 
D intake experience decrease risk (HR 0.63, 95% CI 0.41, 0.96). Tumor thickness was 
inversely correlated with higher levels of education (p < .001) and being White (p < 
.001). Serum vitamin D levels did not seem to predict tumor thickness. The correlation 
between serum vitamin D levels and reported dietary intake of vitamin D was weak (r = 
0.17, p < .001).  
2.1.4 Conclusion 
High reported vitamin D intake in this study seemed to predict an increased risk of 
melanoma among men. When looking at invasive melanoma in women, there was a 
protective effect of increasing levels of vitamin D intake. 
2.2 Introduction 
It is estimated that there will be more than 75,000 cases of melanoma and 
approximately 10,000 melanoma-related deaths in the US in 2016.1 The lifetime risk of 
developing melanoma is 1 in 50.30 Despite the efforts of the medical community, 
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incidence rates of melanoma are still on the rise.31 Limiting exposure to ultraviolet 
radiation, remains the only modifiable risk factor for melanoma. Current preventive 
strategies focus on avoidance of tanning beds, education about sun safe behaviors, and 
proper use of sun block or sun screen.32,33 There is insufficient evidence to concretely 
support or refute most dietary factors as protective or harmful in regards to melanoma 
risk. One of the key dietary suspects in this process is vitamin D; a vitamin produced, in 
part, in the skin using the same radioactive rays that are known to contribute to melanoma 
risk. Finding a balance between this risk and the known benefits of adequate vitamin D 
levels has become paramount. 
The Institute of Medicine (IOM) released its guidelines for vitamin D in 2011 
which immediately attracted criticism as being too conservative (ie, not recommending an 
adequate daily allowance of vitamin D).34,35 According to the IOM, the serum vitamin D 
levels should be above 20ng/ml. A U-shaped distribution was seen when relating vitamin 
D levels to cardiovascular disease, bone injury due to falls, and pancreatic cancer 
suggesting that there is a point of maximum benefit in vitamin D levels. This was 
estimated at approximately 50ng/ml. Using 20ng/ml as a threshold for deficiency, Forrest 
et al showed that more than 41% of the U.S. population would be considered vitamin D 
deficient with more than 80% of African-Americans being deficient.36 It has been 
suggested that a lower limit for normal be set at 30ng/ml.37 Using this level as the cutoff 
might put more than half of the U.S. population in the deficient category.  
Two case-control studies evaluated melanoma risk by dietary vitamin D levels 
assessed by food frequency questionnaires. One of these reported an odds ratio for 
developing melanoma of 0.61 (95% CI 0.40-0.95) when comparing the highest 20% of 
vitamin D levels to the lowest 20%.38 The second study did not detect a difference in risk 
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of melanoma among those who ingested more vitamin D rich foods.39 Three case-control 
studies have evaluated the influence of vitamin D on nonmelanoma skin cancer (NMSC) 
using food frequency questionnaires. One of these showed no relationship (OR = 0.8, 
95% CI 0.58, 1.10), one showed an inverse relationship (OR in highest quartile of vitamin 
D intake = 0.54, 95% CI 0.31, 0.96), and one showed an inverse relationship when 
relying on hip fracture as a surrogate of vitamin D level (OR = 0.90, 95% CI 0.85–
0.94).40-42 
Three case-control studies measured serum vitamin D. Among these, one showed 
no difference in vitamin D levels between melanoma cases and controls,43 one showed 
significantly lower levels of vitamin D in patients with stage IV melanoma compared to 
patients with earlier stage disease,44 and one showed that weekend sun exposure was 
correlated with higher serum vitamin D levels and had a protective effect (OR = 0.46, 
95% CI 0.30-0.72).45 The last of these three studies was the largest but did not include 
serum vitamin D levels on the majority of population based controls, and therefore did 
not report specific data on vitamin D levels. Additionally, these studies did not adjust for 
dietary intake of vitamin D or for small sample size. One large prospective cohort study 
failed to show any relationship between vitamin D and melanoma but was limited by the 
lack of serum vitamin D levels.46 
Tumor thickness, measured microscopically to the hundredth of a millimeter, is 
the most accurate predictor of prognosis in melanoma. The measurement is objective and 
is defined as the thickness of the tumor starting at the granular layer of the epidermis. 
One prospective cohort showed that a 20 nmol/L increase in serum vitamin D levels was 
correlated with a lower tumor thickness at diagnosis (p = .002) and was protective against 
relapse and death (HR = 0.79, 95% CI 0.64–0.96).47 This study seems to be the most 
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persuasive and suggests that higher vitamin D levels may be both protective prior to 
diagnosis and beneficial after diagnosis. A second, smaller prospective cohort looked at 
levels of serum vitamin D at the time of diagnosis and found that low levels of vitamin D 
were associated with thicker melanomas. It did not find that high vitamin D levels were 
associated with a better prognosis.48 Additionally, Saiag et al49 found that fluctuations in 
serum vitamin D levels after melanoma diagnosis conferred a poorer prognosis. 
The effect of vitamin D on melanoma risk has yet to be clearly defined. It is 
apparent that accurately measuring UV exposure (a significant contributor to vitamin D 
levels and melanoma risk, as noted above) presents a formidable obstacle. While there is 
not significant evidence that adequate vitamin D levels are protective against melanoma, 
there is evidence to suggest adequate levels may be beneficial in patients with late stage 
disease.44 This review of the PLCO cohort is the largest U.S. cohort to look at the 
influence of vitamin D on melanoma risk. It also has a benefit of having serum vitamin D 
levels on a subset of the cohort. Finally, tumor thickness (the most important prognostic 
indicator) is available on nearly 500 melanoma cases. 
2.3 Methods 
2.3.1 PLCO Methods 
The PLCO is a population-based randomized trial developed to evaluate the effect 
of screening for prostate, lung, colorectal, and ovarian cancers on cancer specific 
mortality.26,50 The trial included 10 screening centers across the US and enrolled 78,216 
women and 76,685 men all between the ages of 55 and 74 at baseline.26 
At enrollment, PLCO study participants were asked to complete a gender-specific 
baseline questionnaire. Both questionnaires were 8 pages long; the male version included 
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49 questions and the female version included 61 questions. Participants also completed an 
extensive dietary questionnaire that included 156 items over 20 pages. A second dietary 
questionnaire was implemented later in the study allowing for a second measure on some 
participants. Dietary questionnaires are available on more than 125,000 study 
participants. Other data available on these patients include a baseline questionnaire 
including: family history of cancer, demographic data, alcohol/tobacco use, and 
metabolic measurements including weight and height, and reproductive factors. Certain 
oral medication use was collected where relevant. On a limited number of these study 
participants, serum vitamin D levels have also been measured. The dietary questionnaire 
has been validated in three different studies.27-29 Additional details on the methods of this 
trial were published previously.26  
We analyzed the data using Stata/IC 14.1.51 Of the 154,897 PLCO participants, 
111,270 were included in this study (see Figure 2.1). The majority of those excluded did 
not have a self-reported vitamin D intake available (n excluded = 31,293). A smaller 
number did not complete a baseline questionnaire (n excluded = 4,896) or had history of 
cancer prior to the baseline questionnaire (n excluded = 6,848). Of the remaining 
participants, 854 had melanoma.  
Descriptive statistics were used to define the variables of interest for this study. 
Age in years was divided into 4 categories (55–59, 60-64, 65–69, 70 and above). Because 
there were so few non-White PLCO participants who developed melanoma, race was 
categorized into White and non-White categories only. Education categories were divided 
into those who did not finish high school, high school graduates, those who did some 
college or posthigh school education, and college graduates. 
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2.3.2 Vitamin D 
The amount of vitamin D consumed was calculated from the food frequency 
questionnaires and included supplement/vitamin use. Nutrient databases were developed 
for the dietary questionnaire based on the U.S. Department of Agriculture food supply 
database52 and the Nutrition Data System for Research at the University of Minnesota.53 
The nutrient values (including vitamin D) were calculated from the database for each 
subject based on the frequency with which individuals reported they ate/drank each food 
or beverage and the corresponding portion size. Vitamin D intake was reported in 
mcg/day separately for food sources and supplements as well as sum total of all vitamin 
D intake. This variable was divided into quartiles for this study.  
Serum vitamin D levels, reported as ng/ml, were available from 5,906 of the 
PLCO participants. Blood collection was categorized by season of draw to control for 
seasonal variation of vitamin D as follows: December to February, March to May, June to 
August, and September to November. Each season’s quartiles were then combined back 
into one variable to take into account the season of blood draw. In other words, season-
specific quartiles were created, so that the vitamin D quartiles are not simply a reflection 
of the season of blood sample collection (see Table 2.1). Correlations between serum and 
dietary vitamin D levels were calculated using the adjusted quartiles for both.  
2.3.3 UV Exposure 
UV exposure was based on the average UV measure of the study center where the 
person was enrolled. The average UV index for the last 4 years for each city was used to 
generate an average UV index for that city. These numbers were assessed by the 
Environmental Protection Agency and were reported by www.homefacts.com54 as annual 
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averages. For each city, the average of the annual UV index for the years 2011-2015 was 
calculated. High UV index was defined as 5 or greater and low UV index was less than 5 
for the model stratified on UV index.  
2.3.4 Tumor Thickness 
Tumor thickness is recognized as the most accurate prognostic factor in 
melanoma but was not reported to the PLCO. In order to evaluate effects on tumor 
thickness, de-identified pathology reports, if available, were obtained for those 
participants who developed melanoma. Of the 1,432 cases of melanoma, 520 had 
available pathology reports. These were individually reviewed to record tumor thickness 
which was available in 473 cases.  
2.3.5 Statistical Analysis 
Two sample t tests and chi-square analysis were used to evaluate the difference 
between melanoma cases and noncases among demographic groups. A Cox proportional-
hazards model was used to estimate the risk of melanoma based on dietary and serum 
vitamin D levels. A second analysis focused on the subset of participants with invasive 
melanoma and estimated risk by dietary vitamin D only. In this model, univariate analysis 
was used for crude hazard ratios and multivariate analysis included sex, age, average UV 
at study center, education, and race. Additional similar models were used to stratify on 
sex and on high versus low UV centers.  
2.4 Results 
Table 2.2 shows the characteristics of the PLCO cohort participants who 
developed melanoma compared to the PLCO participants who did not. Participants who 
developed melanoma were slightly older (mean age at study entry 63 years) compared to 
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those who did not (mean age at study entry 62.5 years, p = .033). Of participants who 
developed melanoma, more were male than female (62.4% compared to 37.6%, p < 
.001). Melanomas were nearly all seen in White participants (n = 848, 99.3%) with only 6 
(0.7%) cases developing in participants of other races (p < .001). The risk of melanoma 
increased with education level. Those who did not graduate high school represented 6.5% 
of the total population but had less than 3% of the melanomas while those with college 
degrees represented roughly 35% of the population and had 50% of the melanomas (p 
trend < .001). The majority of participants had a BMI within the normal and overweight 
range. The distribution of melanoma did not vary significantly differently by BMI.  
In univariate analysis, the risk of melanoma in participants who reported ingesting 
13.5 mcg/day or more of vitamin D was roughly 1.36 (95% CI 1.12–1.64) times that of 
those who reported ingesting less than 3.86 mcg/day of vitamin D (Table 2.3). This 
hazard ratio reduced to 1.17 (95% CI 0.97–1.42) when adjusted for sex, age, average UV 
at the study center, education, and race. In the univariate analysis, there was a significant 
trend reflecting an increased risk with increased vitamin D consumption (univariate p for 
trend =.006). This trend was not seen in multivariate analysis. When stratifying on sex, an 
increased risk of melanoma was suggested for men with higher vitamin D intake. Among 
participants from low UV centers who were in the highest quartile of vitamin D intake, 
the HR of 1.24 was very close to statistically significant (95% CI 0.99, 1.56). 
Univariate analysis of the subset that excluded in situ melanomas showed 
significant results when looking at male participants in the highest quartile of vitamin D 
intake (Table 2.4). These participants had an increased risk of invasive melanoma (crude 
HR 1.42, 95% CI 1.05, 1.92) but this did not persist in multivariate analysis. There was a 
protective effect seen in multivariate analysis among women who were in the highest 
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quartile of vitamin D intake (HR 0.63, 95% CI 0.41, 0.96). A significant trend was noted 
with increasing vitamin D intake relating to lower invasive melanoma risk (p trend = 
.038).  
When evaluating the subset of participants for whom serum vitamin D 
measurements were available, an association with melanoma was not observed (data not 
shown). In this subset, an intra-participant correlation between the self-reported dietary 
vitamin D quartiles and objective serum vitamin D quartiles taking into account the 
season of draw was seen (r = .17, p < .001).  
In multivariate linear regression, vitamin D intake did not seem to influence the 
tumor thickness in the cases where a path report was accessible (Table 2.5). Factors that 
did influence tumor thickness included race and education. Tumor thickness increased 
with higher levels of education (p for trend < .001) and was, on average 2.9 mm greater 
among those with a race other than White (p < .001).  
2.5 Discussion 
This study suggests that higher intake of vitamin D does not generally protect 
against melanoma. In fact, males in the highest quartiles of vitamin D intake may have an 
increased risk of melanoma. The small cohort studied by Wyatt et al48 seemed to suggest 
this point as well. Furthermore, the subset excluding in situ melanomas showed an 
association between low levels of vitamin D (those in the second to lowest quartile) and 
risk of invasive melanoma in those who were in high UV areas. This pattern, namely 
lower levels of vitamin D increasing risk and higher levels not being protective has also 
been described in the literature.49 This likely reflects a complex biological interaction 
between melanoma and vitamin D and may also reflect the difficulty to control for UV 
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exposure adequately.55,56 It may hint at a paradoxical influence of vitamin D on 
melanoma disease inception compared to disease progression. 
When considering only invasive melanomas among women, however, there seems 
to be a protective effect. Not only was there a significant protective benefit from vitamin 
D intake among woman in the highest quartile, but there was also a trend suggesting 
decreased risk with increasing vitamin D intake. This may highlight a biological 
difference of melanoma in women compared to men as suggested by Nosrati et al57  
The fact that risk related to higher vitamin D was higher for those who enrolled at 
a low UV index center was unexpected. While this would support the argument that 
vitamin D increases the risk of melanoma independently, it may also be the result of 
unmeasured confounders. It is possible that those participants with the highest levels of 
vitamin D intake include those who are aware of vitamin D health benefits. This group is 
likely to get more UV exposure in an effort to ensure higher levels of vitamin D in 
combination with adequate or high dietary intake. The use of average UV indices at the 
study center would not adequately control for the variability within the participants at 
each study center. Conversely, albeit less likely, it is possible that higher vitamin D intake 
is somehow independently related to melanoma risk. 
While there did not seem to be an association between vitamin D intake and tumor 
thickness, there was the suggestion of a trend towards deeper tumors in higher quartiles 
of vitamin D intake. The fact that non-White race and lower education level58 (as a proxy 
for socioeconomic status) may be correlated with a deeper tumor has been described in 
other studies. There is also clear evidence that the rate of low vitamin D is more 
prominent among non-White races. It is possible that a higher number of invasive 
melanomas with accurate tumor thicknesss might have pushed these data towards more 
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significance. In other words, perhaps we did not have adequate statistical power to detect 
associations with tumor thickness. Because there were few participants with both serum 
vitamin D and tumor thickness, we were unable to analyze the association between these 
two factors. 
This study is novel in two ways. First, it is among the few that also evaluated 
serum vitamin D levels prior to the diagnosis of melanoma, and second, we attempted to 
correlate serum levels and self-reported intake while controlling for season of blood 
draw. The correlation between these two measures was positive but relatively weak. 
Dietary vitamin D did not influence tumor thickness and weakly correlated with serum 
levels. These data suggest that careful monitoring of serum levels, dietary levels, and UV 
exposure in a prospective fashion may be the best approach to further studying these 
possible associations. 
The size of the study population and the data available over a 13 year period for 
each participant provides strength to the findings. It is among the first of its size based on 
a cohort in the US. It included an a priori validated food frequency questionnaire as well 
as detailed questionnaires and data collection about potential covariates/confounders. Due 
to the methods of collection and the accuracy of the study timeline, there is also less 
temporal ambiguity between data collection, blood sample vitamin D measures, and 
incident melanoma.  
Oral intake of vitamin D was assessed by a self-reported food frequency 
questionnaire that may not have been done at the same time as the serum draw. The lack 
of temporal correspondence in some cases between completing the intake assessment and 
serum collection may have reduced the amount of correlation between the two measures. 
However, a study of long term stability of vitamin D levels within the PLCO suggests 
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relative long term stability despite seasonal variation over 5 years (Spearman correlation 
coefficient 0.53). 59 Understanding the long term stability makes the effect of temporal 
variation seem less likely to have significantly impacted the results of this study. Other 
limitations include the lack of serum vitamin D levels on all participants and the lack of 
tumor thickness on a portion of the melanoma cases. A better method to control for UV 
exposure and socioeconomic status might also improve the accuracy of findings. Our 
study used the UV indices at the study center as a proxy of UV indices at the participant’s 
home. Using each participant’s zip code or partial zip code may have allowed more 
accuracy. In addition, each participant’s occupation and hobbies may influence how 
much UV exposure they get and should be controlled for. On the other hand, it is not 
likely that occupation and hobbies would influence vitamin D consumption. 
2.6 Conclusion 
The rates of melanoma in the PLCO trial were consistent with the published rates 
in the US, suggesting that the PLCO population is a representative sample. Known 
disparities based on race and economic status are reinforced and must continue to be 
addressed.  
High reported vitamin D intake in this study was associated with an increased risk 
of melanoma among men. This does not fit with the findings in the rest of the 
literature42,46,56 and may call into question the adequacy of self-reported measures to 
estimate vitamin D. However, our study showed a correlation between the self-reported 
measures and the serum levels, where available. Further research may elucidate better 
boundaries of where using these methods is appropriate. 
When looking at invasive melanoma in women, there was a protective effect of 
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increasing levels of vitamin D intake. Because we did not have serum levels available, 
further studies to evaluate this effect are necessary. Additionally, melanoma biology may 
be different between men and women particularly when it comes to vitamin D. 
When combining the literature and the findings of this study, it seems likely that 
low levels of vitamin D connote higher risk of melanoma while higher levels do not 
appear to be protective. As low levels of vitamin D are common and known risk factors 
for many other diseases,60-67 it seems reasonable to encourage screening and 
supplementation. Further investigation before recommending supplementing with vitamin 
D for groups with higher risk of melanoma seems warranted. Future prospective studies 




Figure 2.1. CONSORT Diagram for Vitamin D. 
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Table 2.1. Serum Vitamin D Ranges by Season of Draw and Quartile (ng/ml) 
Quartile Winter Spring Summer Fall 
     
1 3.2–16.3 2.5–16.4 3–21.1 4.1–20.6 
2 16.4–21.3 16.5–21.7 21.2–26 20.7–26.1 
3 21.4–27.3 21.8–27.5 26.1–32 26.2–31.9 
4 27.4–75.5 27.6–70.8 32.1–89.4 32–72.8 





Table 2.2. Comparison of Characteristics of Participants Who Developed Melanoma to 
Those Who Did Not  
Characteristic  Melanoma  No melanoma  p 
         
Average age (in years)  854 63.0  110,416 62.5  .033 
         
  n %  n %   
Categories by age (in years)         
<60  252 29.5  37,093 33.6   
60–64  260 30.4  34,311 31.1   
65–69  223 26.1  24,927 22.6   
≥70  118 13.8  14,085 12.8   
         
Sex         
Male  533 62.4  54,469 49.3   
Female  321 37.6  55,947 50.7  <.001 
         
Race         
White  848 99.3  99,874 90.5   
Other  6 0.7  10,542 9.5  <.001 
         
BMI         
<18.5  8 0.9  711 0.6   
18.5–24.9  269 31.5  35,678 32.3   
25–29.9  391 45.8  46,621 42.2   
≥30  175 20.5  25,913 23.5   
Missing  11 1.3  1,493 1.4  .132 
         
Education         
Did not graduate high school  25 2.9  7,136 6.5   
High school graduate  130 15.2  25,893 23.5   
Some college or posthigh school training  266 31.1  37,889 34.3   
College graduate  430 50.4  39,273 35.6   
Missing  3 0.4  225 0.2  <.001 
         
Note. Chi-square analysis.  
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Table 2.3. Vitamin D and Risk of Melanoma 
Characteristic 
Crude hazard ratio  
(95% CI) p 
Multivariate hazard 
ratio (95% CI) p 
Dietary vitamin D estimate (mcg/day)a 
Dietary D q1 (<3.86) 1.00  1.00  
Dietary D q2 (3.86–10.73) 1.19 (0.98, 1.45) .083 1.06 (0.87, 1.29) .555 
Dietary D q3 (10.74–13.49) 1.09 (0.89, 1.33) .394 1.05 (0.85, 1.28) .665 
Dietary D q4 (≥13.5) 1.36 (1.12, 1.64) .002 1.17 (0.97, 1.42) .109 
p trend  .006  .129 
     
Serum vitamin D (n = 6,729)b 
Quartile 1 1.00  1.00  
Quartile 2 0.86 (0.38, 1.92) .711 1.02 (0.47, 2.21) .961 
Quartile 3 1.21 (0.58, 2.52) .609 0.84 (0.37, 1.92) .686 
Quartile 4 1.35 (0.66, 2.79) .410 1.59 (0.78, 3.26) .205 
p trend  .214  .236 
     
Risk of melanoma stratified by sexc 
Male     
Dietary D q1 (<3.86) 1.00  1.00  
Dietary D q2 (3.86–10.73) 1.17 (0.91, 1.50) .214 1.09 (0.85, 1.39) .517 
Dietary D q3 (10.74–13.49) 1.18 (0.90, 1.54) .237 1.07 (0.82, 1.40) .617 
Dietary D q4 (≥13.5) 1.44 (1.13, 1.83) .003 1.27 (0.99, 1.61) .055 
p trend  .003  .058 
     
Female     
Dietary D q1 (<3.86) 1.00  1.00  
Dietary D q2 (3.86–10.73) 1.12 (0.80, 1.55) .515 1.03 (0.74, 1.43) .874 
Dietary D q3 (10.74–13.49) 1.10 (0.81, 1.49) .530 1.00 (0.74, 1.35) .994 
Dietary D q4 (≥13.5) 1.17 (0.85, 1.61) .326 1.02 (0.74, 1.40) .912 
p trend  .362  .957 
     
Risk of melanoma stratified by UVd 
High UV     
Dietary D q1 (<3.86) 1.00  1.00  
Dietary D q2 (3.86–10.73) 1.07 (0.73, 1.56) .727 0.89 (0.61, 1.31) .579 
Dietary D q3 (10.74–13.49) 0.86 (0.58, 1.26) .439 0.80 (0.54, 1.18) .256 
Dietary D q4 (≥13.5) 1.23 (0.86, 1.77) .252 0.98 (0.68, 1.41) .925 
p trend  .445  .850 
     
Low UV     
Dietary D q1 (<3.86) 1.00  1.00  
Dietary D q2 (3.86–10.73) 1.24 (0.99, 1.56) .067 1.12 (0.89, 1.42) .321 
Dietary D q3 (10.74–13.49) 1.19 (0.94, 1.51) .144 1.16 (0.91, 1.47) .223 
Dietary D q4 (≥13.5) 1.41 (1.13, 1.77) .003 1.24 (0.99, 1.56) .058 
p trend  .006  .061 
a  Covariates include gender, age, average UV at study center, education, and race. 
b  Based on season of draw, see Table 2.1 for ranges 
c  Covariates include age, average UV at study center, education, and race 
d  Covariates include gender, age, education, and race 
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Table 2.4. Vitamin D and Risk of Invasive Melanoma  
Characteristic 
Crude hazard ratio 
(95% CI) p 
Multivariate hazard 
ratio (95% CI) p 
Dietary vitamin D estimate (mcg/day)a 
Dietary D q1 (<3.86) 1.00  1.00  
Dietary D q2 (3.86–10.73) 1.05 (0.82, 1.35) .669 0.93 (0.73, 1.20) .611 
Dietary D q3 (10.74–13.49) 1.00 (0.78, 1.28) .979 0.97 (0.76, 1.25) .841 
Dietary D q4 (≥13.5) 1.15 (0.91, 1.47) .247 0.99 (0.78, 1.26) .785 
p trend  .331  .948 
     
Risk of melanoma stratified by sexb 
Male     
Dietary D q1 (<3.86) 1.00  1.00  
Dietary D q2 (3.86–10.73) 1.14 (0.84, 1.56) .397 1.07 (0.78, 1.46) .678 
Dietary D q3 (10.74–13.49) 1.25 (0.89, 1.74) .193 1.13 (0.81, 1.58) .468 
Dietary D q4 (≥13.5) 1.42 (1.05, 1.92) .022 1.26 (0.93, 1.70) .139 
p trend  .018  .117 
     
Female     
Dietary D q1 (<3.86) 1.00  1.00  
Dietary D q2 (3.86–10.73) 0.83 (0.54, 1.26) .371 0.77 (0.51, 1.17) .222 
Dietary D q3 (10.74–13.49) 0.84 (0.57, 1.22) .359 0.77 (0.52, 1.12) .172 
Dietary D q4 (≥13.5) 0.72 (0.47, 1.10) .127 0.63 (0.41, 0.96) .032 
p trend  .145  .038 
     
Risk of melanoma stratified by UVc 
High UV     
Dietary D q1 (<3.86) 1.00  1.00  
Dietary D q2 (3.86–10.73) 1.09 (0.66, 1.78) .746 0.90 (0.55, 1.48) .682 
Dietary D q3 (10.74–13.49) 0.78 (0.46, 1.30) .340 0.73 (0.43, 1.22) .229 
Dietary D q4 (≥13.5) 1.28 (0.80, 2.05) .303 1.01 (0.63, 1.61) .983 
p trend  .532  .894 
     
Low UV     
Dietary D q1 (<3.86) 1.00  1.00  
Dietary D q2 (3.86–10.73) 1.05 (0.79, 1.39) .757 0.95 (0.71, 1.26) .716 
Dietary D q3 (10.74–13.49) 1.08 (0.81, 1.44) .592 1.07 (0.80, 1.42) .654 
Dietary D q4 (≥13.5) 1.11 (0.84, 1.47) .466 0.98 (0.74, 1.30) .884 
p trend  .445  .798 
     
a  Covariates include gender, age, average UV at study center, education, and race. 
b  Covariates include age, average UV at study center, education, and race 









(95% CI) p  
Multivariate  
(95% CI) p 
       
Dietary vitamin D estimate 
(mcg/day) 
      
Dietary D q1 (<3.86)  —   —  
Dietary D q2 (3.86–10.73)  -0.24 (-0.63, 0.14) .219  -0.04 (-0.42, 0.33) .830 
Dietary D q3 (10.74–13.49)  0.03 (-0.36, 0.42) .890  0.27 (-0.11, 0.65) .166 
Dietary D q4 (≥13.5)  0.08 (-0.29, 0.45) .683  0.23 (-0.13, 0.59) .205 
p trend   .325   .076 
       
Race       
White  —   —  
Non-White  3.33 (2.14, 4.51) <.001  2.90 (1.62, 4.18) <.001 
       
Sex       
Male  —   —  
Female  -0.09 (-0.33, 0.15) .441  -0.09 (-0.36, 0.19) .533 
       
Study center UV  0.02 (-0.04, 0.08) .538  0.12 (-0.03, 0.26) .107 
       
Education level       
Did not graduate high school  —   —  
High school graduate  -1.25 (-1.97, -0.54) .001  -0.37 (-1.20, 0.46) .382 
Some college or posthigh school  -1.67 (-2.36, -0.99) <.001  -0.92 (-1.71, -0.14) .021 
College grad  -1.74 (-2.42, -1.07) <.001  -0.99 (-1.76, -0.22) .012 
p trend   .001   .001 
       










BODY MASS INDEX, TUMOR THICKNESS, AND  
 
MELANOMA RISK WITHIN THE PROSTATE,  
 





The incidence of melanoma continues to increase despite public awareness 
campaigns directed at reducing exposure to ultraviolet (UV) light. Other than UV light 
exposure, there are few modifiable factors that are known to prevent or reduce severity of 
melanoma. Previous literature has suggested an increased risk of melanoma in people 
with higher body mass index (BMI).  
3.1.2 Methods 
The Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer cohort followed more 
than 150,000 people for 13 years. Each participant’s health status was tracked and 
participants were asked to fill out multiple surveys, including a food frequency 
questionnaire. Health histories and demographic information were collected from each 
participant at the time of enrollment and are available for study. Over 1300 of these 
participants developed melanoma. Using these data, the relationship between BMI at age 
20 and melanoma was explored. Both univariate and multivariate Cox regressions were 
27 
 
used as well as univariate and multivariate linear regression.  
3.1.3 Results 
Using the standard categories of BMI, the risk of melanoma in participants with a 
low BMI (<18.5) at age 20 was decreased when compared to participants who had a 
normal BMI (normal BMI range 18.5–24; HR = 0.68, 95% CI 0.53, 0.88). When 
stratified on sex, the reduced risk of melanoma associated with low BMI at age 20 
persisted in males (HR = 0.58, 95% CI 0.38, 0.87) while the opposite was seen in 
females, in whom a reduced risk for melanoma approached significance in those who 
were considered overweight (BMI 25–29) at age 20 (HR = 0.62, 95% CI 0.38, 1.01). 
Percent weight gain between age 20 and age 50 may be associated with melanoma risk in 
multivariate analysis (HR = 0.71, 95% CI 0.49, 1.02). BMI did not have a significant 
influence on tumor thickness.  
3.1.4 Conclusion 
The risk of melanoma may be influenced by BMI during young adulthood. This 
risk differs between men and women. A protective association was observed in men with 
low BMI at age 20. A similar protective association was observed in women who were 
overweight at age 20. 
3.2 Introduction 
It is estimated that there were roughly 75,000 cases of melanoma and nearly 
10,000 melanoma-related deaths in the US in 2015.30 The lifetime risk of developing 
melanoma is 1 in 50.30 Despite efforts to educate about and prevent melanoma, incidence 
rates are still on the rise.31 Exposure to ultraviolet radiation remains the only modifiable 
risk factor. Current preventive strategies focus on avoidance of tanning beds, education 
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on sun safe behaviors, and proper use of sun block or sun screen.32,33 Because of the 
increased body surface area, obesity has also been implicated as a risk factor although not 
proven. 
Obesity is at epidemic proportions. More than 35% of men and 40% of women 
are obese, and the rate is increasing in women.68,69 Obesity is known to contribute to 
many health concerns. An association between BMI and melanoma has been inconsistent 
across studies.  
Among the largest studies conducted, Thune et al reviewed a database of over 1.3 
million people in Norway.19 There were more than 4,900 cases of melanoma in this 
cohort over a 12 year period. This large cohort showed slightly elevated melanoma risk 
for males in the highest quintile of BMI (RR = 1.26, 95% CI 1.10, 1.45).  
Dennis et al reported a significant odds ratios for melanoma among individuals 
with elevated BMIs in a U.S. cohort.70 The OR for melanoma among individuals with 
BMI of 25 or higher was 2.55 (95% CI 1.52, 4.53) and those with the highest BMI had on 
OR for melanoma of over 2.0.  
The Me-Can (Metabolic Syndrome and Cancer Project71) study evaluated 
melanoma risk factors among multiple large European cohorts. Again, an increased BMI 
was associated with an increased risk of melanoma in quintiles 2-5 when compared to the 
lowest quintile of BMI. In women, an increased risk of melanoma was seen only in the 
2nd to lowest quintile (HR = 1.42, 95% CI 1.09, 1.86). An increased risk of fatal 
melanoma was also seen in this study for all participants who were in the highest quintile 
of BMI (HR = 1.61, 95% CI 1.00, 2.61). While mortality data related to melanoma is not 
available for the PLCO cohort, melanoma tumor thickness remains the most accurate 
prognosticator. Little is known about the influence of BMI on melanoma tumor thickness. 
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In a meta-analysis conducted by Sergentanis et al where the pooled effect estimate 
from 15 studies was found to be 1.31 (95% CI 1.18, 1.45) among overweight and obese 
men.18 A large Danish prospective cohort failed to find any relationship between BMI 
and melanoma.72  
A separate study of 1171 Australian men and women suggested that height might 
be associated with melanoma risk in men (RR per 5cm increment = 1.55; 95% CI 0.97–
2.47, p = .067)22, an association also seen by Thune et al19 One attempt to explain the 
physiologic relationship focuses on larger body surface area. This theory seems to be 
refuted by the lack of a corresponding dose response between BMI and melanoma risk 
and a complete lack of this relationship among women.20  
The aim of our study was to investigate the possible association between BMI at 
age 20, percent weight change from age 20 to 50, and the risk of melanoma in a cohort 
study. We also aim to evaluate what influence BMI might have on tumor thickness. 
3.3 Methods 
3.3.1 PLCO Methods 
The PLCO is a randomized trial developed to evaluate the effect of screening for 
prostate, lung, colorectal, and ovarian cancers on cancer specific mortality. The trial 
included 10 screening centers across the US and enrolled 78,216 women and 76,685 men 
between the ages of 55 and 74. Participants were excluded if they were currently 
undergoing treatment for cancer or had been previously diagnosed with one of the four 
cancers being studied, had surgical removal of colon, lung, or prostate, were on another 
cancer screening/prevention trial, or had colonoscopy, sigmoidoscopy, or barium enema 
in the 3 years prior to enrolling. Men were excluded if they were taking finasteride in the 
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6 months prior to enrolling or if they had more than one PSA test in the 3 years prior to 
enrollment. Before October 1996, women with previous surgical removal of both ovaries 
were excluded. Before April 1, 1999, women were excluded from the trial if they were 
currently taking or had taken tamoxifen or raloxifene in the 6 months prior to 
randomization. 
Each participant completed a baseline questionnaire and a validated dietary 
questionnaire.27-29 After meeting inclusion criteria, each participant was randomized into 
the intervention arm (receiving intervention screening for the targeted cancers) or the 
control arm (standard of care). Those in the intervention arm received PLCO cancer 
specific screening for the first 6 years and were then followed for 7 additional years. The 
screening exams included a flexible sigmoidoscopy and chest x-ray for all participants; 
men received digital rectal exam and PSA, while women received transvaginal ultrasound 
and CA-125. Those in the control arm received standard of care and were followed for 13 
years. Enrollment took place at the 10 study centers from 1993 until 2001. Additional 
details on the methods of this trial were published previously.26  
We analyzed the data using Stata/IC 14.1.51 Of the 154,897 PLCO participants, 
143,036 were included in this study (see Figure 3.1).  
Descriptive statistics were used to define the variables of interest for this study. 
Age in years was divided into 4 categories (55-59, 60-64, 65-69, 70-78). Because there 
were so few non-White PLCO participants who developed melanoma, race was 
categorized into White and non-White categories only. Education categories were divided 
into those who did not finish high school, high school graduates, those who completed 
some college or posthigh school education, and college graduates. 
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3.3.2 UV Exposure 
UV exposure was based on the average UV measure of the study center where the 
person was enrolled. The average UV index for the last 4 years for each city was used to 
generate an average UV index for that city. These numbers were assessed by the 
Environmental Protection Agency and were reported by www.homefacts.com54 as annual 
averages. For each city, the average of the annual UV index for the years 2011-2015 was 
calculated. High UV index was defined as 5 or greater and low UV index was less than 5 
for the model stratified on UV index.  
3.3.3 Tumor Thickness 
Tumor thickness is recognized as the most important prognostic factor in 
melanoma but was not reported to the PLCO. In order to evaluate effects on tumor 
thickness, de-identified pathology reports were obtained, if available, for those 
participants who had melanoma. Of the 1,432 cases of melanoma, 520 had available 
pathology reports. These were individually reviewed to record tumor thickness, which 
was available in 473 cases.  
3.3.4 Body Mass Index  
BMI was reported by study participants as they enrolled in the PLCO trial. They 
were asked to recall their weight and height at age 20 and age 50. Weight and height at 
study entry was also recorded. BMI was categorized to standard ranges: below 18.5 
(underweight), 18.5-24.9 (normal), 25-29.9 (overweight), and 30 and above (obese). 
Weight change was also calculated as a percentage by dividing the difference between 
weight at age 20 and weight at age 50 by weight at age 20. This was multiplied by 10 to 
create a continuous variable in 10% increments. 
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3.3.5 Statistical Analysis 
Two-sample t tests (continuous variables) and chi-square tests (categorical 
variables) were used to evaluate the difference between melanoma cases and the rest of 
the cohort for demographic factors. A Cox proportional-hazards model was used to 
estimate the risk of melanoma based on BMI at age 20. In this model, univariate analysis 
was used for crude HRs and multivariate analysis included sex, age, height, average UV 
at study center, education, and race. Both univariate and multivariate linear regression 
were used to evaluate a potential relationship between BMI at age 20 and melanoma 
tumor thickness. The multivariate model included sex, race, study center UV index (high 
vs. low), and education level. 
3.4 Results 
Participants who developed melanoma were slightly older (mean age at study 
entry 63 years) compared to those who did not (mean age at study entry 62.6 years, p = 
0.016). Melanomas were nearly all seen in White participants (n = 1,302; 99.0%) with 
only 13 (1.0%) cases developing in other races (p < .001). The risk of melanoma 
increased with education level. The majority of participants had a BMI within the normal 
or overweight ranges. The distribution of melanoma did not vary significantly by BMI 
(see Table 3.1).  
In multivariate analysis (Table 3.2), a significantly reduced risk of melanoma 
among participants in the lowest BMI category (underweight) was observed (HR = 0.68, 
95% CI 0.53, 0.88) as well as in those who were overweight (HR = 0.85, 95% CI 0.72, 
0.99). When stratified on sex, the reduced risk of melanoma associated with low BMI at 
age 20 persisted in males (HR = 0.58, 95% CI 0.38, 0.87) and bordered on significance in 
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females (HR = 0.75, 95% CI 0.52, 1.02). A more significant shift of the protective effect 
was seen in overweight females (BMI 25–29 kg/m2), who had a reduced risk of 
melanoma (HR = 0.62, 95% CI 0.38, 1.01) compared to normal weight women. A 
significant benefit was seen in obese females (HR = 0.78, 95% CI 0.32, 1.88).  
As weight increased (10% increments) between age 20 and age 50 the decrease in 
risk bordered on significance (HR = 0.97, 95% CI 0.93, 1.00; p = .07).  
BMI was not associated with melanoma tumor thickness (see Table 3.3). Race 
other than White was associated with a deeper tumor thickness (univariate coefficient 
3.33, 95% CI 2.14, 4.51; multivariate coefficient 2.93, 95% CI 1.75, 4.12). Less 
education also correlated with a deeper tumor thickness (see Table 3.3). Compared to 
those who did not graduate high school, those with a high school degree had a tumor 
thickness nearly 1mm less (-0.96, 95% CI -1.67, -0.25; p = .008) on average. Those with 
some college or posthigh school education had a tumor thickness nearly 1.5mm less (-
1.43, 95% CI -2.10, -0.75; p < .001). Those with a college or postgraduate degree had a 
tumor thickness 1.52 mm less (95% CI -2.18, -0.85; p < .001). 
3.5 Discussion 
Our study found a reduced risk of melanoma among those who were considered 
underweight at age 20. No increased risk was seen in those who were overweight or 
obese. Additionally, weight change from age 20 to 30 did not seem to influence risk. BMI 
did not seem to influence tumor thickness. 
This study may represent the largest U.S.-based cohort to examine the relationship 
between BMI and melanoma. It is novel in that it evaluates the relationship between 
melanoma and BMI at age 20, as it is thought that a significant proportion of UV skin 
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damage is accumulated in these younger years. The primary association in the literature 
seems to be association between BMI and melanoma among men but not women.71 The 
direction of the relationship in the literature suggests increased risk with increased BMI 
but does not seem to represent a dose response curve. 
This study suggests that men who are underweight at age 20 had a decreased risk 
of melanoma in later years. Furthermore, as a person’s weight increased, their risk of 
melanoma probably decreased. While this does not disprove the idea that higher BMI is 
associated with higher risk of melanoma, it calls this assumption into question as well as 
the theory that body surface area explains that risk. It seems likely that melanoma risk 
behaviors at a younger age vary by BMI and influence risk in later years. While the same 
relationship between BMI and melanoma is not seen in women, the theory that BMI 
influences melanoma risk behaviors at younger ages may explain the decreased risk in 
women who are overweight during these socially formative years. Further research is 
necessary on this point especially in light of the lack of a protective benefit for women 
who were obese at age 20.  
Regardless of the exact causes of the association, this study shows an association 
between BMI at age 20 and risk of melanoma later in life. It is important to recognize that 
there are other biologic factors that may modify the effects of BMI and UV exposure and 
obscure the association when looking at BMI in later adulthood. 
This study represents a very large and geographically diverse U.S.-based 
population. Having BMI at age 20 and confirmed cases of melanoma in such a large 
cohort is an obvious strength. Data on confounding factors included in the PLCO are also 
a strength. The largest weakness of this study is the lack of adequate UV exposure data 
for participants. This limitation is nearly ubiquitous in studies of this type. This 
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shortcoming includes a lack of occupation and hobbies which inevitably influence UV 
exposure. Future studies might prospectively collect these specific data points in addition 
to BMI and evaluate if controlling for these might show a more predictable association 
with melanoma. 
3.6 Conclusion 
The rates of melanoma in the PLCO population are similar to those published for 
the US, suggesting that the PLCO population is a representative sample. Accepting the 
potential modifying influence of biologic differences between men and women on the 
confounding influence of UV exposure does not seem to negate an apparent dichotomy in 
the direction of the association between sexes. It seems likely that BMI mediates the risk 
of melanoma primarily by influencing social and risk behaviors such as clothing choices 
combined with outdoor activities. This would be supported by the suggested decreased 
risk in those who gain weight from age 20 to 50.  
Further research is warranted to understand these behaviors in a prospective 
manner. As the relationship among BMI, UV risk behaviors during young adulthood, and 




Figure 3.1. CONSORT Diagram for BMI and Melanoma in the PLCO.
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Table 3.1. Comparison of Participants Who Developed Melanoma to Those Who Did 
Not  
Characteristic  Melanoma  No melanoma  p 
         
Average age (in years)  1,315 63  141,271 62.6  .016a 
         
  n %  n %   
Categories by age (in years)         
<60  390 29.7  47,355 33.4   
60–64  399 30.3  43,754 30.9   
65–69  341 25.9  31,851 22.5   
≥70  185 14.1  18,761 13.2  .004b 
         
Sex         
Male  828 63.0  71,287 50.3   
Female  487 37.0  70,434 49.7  <.001b 
         
Race         
White  1,302 99.0  124,958 88.2   
Other  13 1.0  16,763 11.8  <.001b 
         
BMI         
<18.5  66 5.0  11,153 7.9   
18.5–24.9  1,037 78.9  106,220 75.0   
25–29.9  171 13.0  19,076 13.5   
≥30  23 1.7  2,651 1.9   
Missing  18 1.4  2,621 1.8  .001b 
         
Education         
Did not graduate high school  44 3.3  10,530 7.4   
High school graduate  202 15.4  32,587 23.0   
Some college or posthigh school training  405 30.8  48,596 34.3   
College graduate  660 50.2  49,638 35.0   
Missing  4 0.3  370 0.3  <.001b 
         
a Two-tailed t test 
 
b Chi-square test 
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Table 3.2. BMI and Risk of Melanoma 
BMI at age 20a 
Crude hazard ratio  
(95% CI) p 
Multivariate hazard 
ratio (95% CI)a p 
     
Full sample     
<18.5 0.62 (0.48, 0.79) <.001 0.68 (0.53, 0.88) .003 
18.5–24 1.00  1.00  
25–29 0.95 (0.80, 1.11) .498 0.85 (0.72, 0.99) .046 
≥30 0.96 (0.64, 1.45) 0.849 1.01 (0.66, 1.54) 0.980 
p trend  .071  .0732 
     
Male onlyb     
<18.5 0.59 (0.39, 0.90) .014 0.56 (0.38, 0.87) .010 
18.5–24 1.00  1.00  
25–29 0.87 (0.73, 1.04) .133 0.89 (0.75, 1.06) .203 
≥30 1.06 (0.66, 1.69) .725 1.12 (0.69, 1.81) .657 
p trend  .841  .598 
     
Female onlyb     
<18.5 0.74 (0.54, 1.01) .055 0.75 (0.54, 1.02) .070 
18.5–24 1.00  1.00  
25–29 0.55 (0.34, 0.89) .015 0.62 (0.38, 1.01) .053 
≥30 0.62 (0.26, 1.51) .294 0.78 (0.32, 1.88) .573 
p trend  .619  .983 
     
Each 10% weight increase from 
age 20 to age 50  
0.93 (0.90, 0.96) <.001 0.97 (0.93, 1.00) .070 
     
a  Controlling for age at enrollment, sex, race, study center UV, and education level 
 
b  Controlling for age at enrollment, race, study center UV, and education level 
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Table 3.3. Multivariate Linear Regression of Melanoma Tumor Thickness. BMI, Sex, 





(95% CI) p  
Multivariate  
(95% CI)a p 
       
BMI at age 20       
<18.5  -.040 (-0.96, 0.17) .168  -0.31 (-0.85, 0.22) .251 
18.5–24  —   —  
25–29  0.05 (-0.26, 0.37) .743  0.00 (-0.30, 0.31) .987 
≥30  -0.42 (-1.29, 0.45) .346  -0.45 (-1.28, 0.38) .289 
       
Sex       
Male  — —  — — 
Female  -0.09 (-0.33, 0.14) .441  -0.12 (-0.36, 0.12) .327 
       
Race       
White  — —  — — 
Non-White  3.33 (2.14, 4.51) <.001  2.93 (1.75, 4.12) 000 
       
Study center UV       
Low  — —  — — 
High  0.02 (-0.04, 0.08) .538  0.16 (-0.08, 0.39) .595 
       
Education level       
Did not graduate high school  — —  — — 
High school graduate  -1.25 (-1.97, -0.55) .001  -0.96 (-1.67, -0.25) .008 
Some college or posthigh school  -1.67 (-2.36, -0.99) .001  -1.43 (-2.10, -0.75) .001 
College grad  -1.74 (-2.42, -1.07) .001  -1.52 (-2.18, -0.85) .001 
       










THE INFLUENCE OF HEIGHT ON RISK OF MELANOMA 
 
AND TUMOR THICKNESS WITHIN THE PROSTATE,  
 





Melanoma is among the most frequently diagnosed cancers and, in later stages, is 
aggressive and hard to treat. Other than ultraviolet (UV) light exposure, there are few 
modifiable factors that are known to prevent or reduce severity of melanoma. Previous 
literature has suggested an increased risk of melanoma in taller people.  
4.1.2 Methods 
The Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer cohort followed more 
than 150,000 people for 13 years each. Each participant’s health status was tracked and 
participants were asked to fill out multiple surveys. Health histories and demographic 
information were collected from each participant at the time of enrollment and are 
available for study. Over 1300 participants developed melanoma. Using these data, the 
relationship between height and melanoma was explored. Cox regression was used to 





In general and when stratified on sex, there was a significant trend for increasing 
risk of melanoma with increasing height (p < .001). These significant trends persisted in 
multivariate analysis with an overall p for trend under .001, a p for trend in men of .037, 
and a p for trend in women of .003. The tallest quartile had a significantly increased risk 
of melanoma compared to the shortest. Height had no effect on melanoma tumor 
thickness. 
4.1.4 Conclusion 
A consistent linear relationship is noted between increasing height and risk of 
melanoma. It is possible that biologic processes that contribute to height may make 
individuals more susceptible to UV radiation damage. 
4.2 Introduction 
It is estimated that there were 75,000 cases of melanoma and 10,000 melanoma-
related deaths in the US in 2016.1 The lifetime risk for a person living in the US of 
developing melanoma is 1 in 50. Despite efforts to educate and prevent, incidence rates of 
melanoma are still on the rise.31 Exposure to ultraviolet radiation, whether natural or not, 
remains the only modifiable risk factor. Current preventive strategies focus on avoidance 
of tanning beds, education of sun safe behaviors, and proper use of sun block or sun 
screen.32,33 Anthropometric (factors that quantify the size and shape of the human body) 
risk factors have been evaluated in some settings and suggest higher risk of melanoma in 
some demographics.  
Theories that might explain a potential relationship between these factors and 
melanoma include the thought that increased body surface area and or their influence on 
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behavior (UV exposing behaviors in particular) portend higher risk of melanoma. 
Another theory is that the biologic factors leading to larger body size (human growth 
hormone) might alter the susceptibility of skin to UV driven mutations. 
In a previous study, we evaluated a potential association between BMI at age 20 
and melanoma risk using the PLCO cohort. While the findings suggested a reduced risk 
of melanoma in underweight men (HR = 0.68, 95% CI 0.53, 0.88) and in overweight 
women (HR = 0.62, 95% CI 0.38, 1.01), there were not associated dose response curves 
to suggest that BMI was the driving factor. Height was therefore evaluated as a potential 
modifier in this relationship. 
A number of ecological studies have evaluated the risk of multiple cancers based 
on population height. Jiang et al looked at 24 different cancer sites and found that 
increased average population height was associated with increased cancer risk at most 
sites, including melanoma. Other studies have also suggested a similar association and 
include melanoma as one of the cancers evaluated.73-80 While these findings suggest that 
factors related to height also are related to cancer risk, none of these studies focused 
solely on melanoma and therefore, in some cases, lacked adequate control for 
confounders, primarily UV exposure. 
One of the paramount studies looking at height as it pertains to melanoma risk 
was performed by Thune et al in 1993. This study looked at a cohort of roughly 1.3 
million people between the ages of 30 and 84 in Norway and adjusted for age, birth 
cohort, geographic location, and BMI. In this cohort, there were approximately 5000 
incident melanomas. Height was broken into 5 relatively equal categories. They found 
that risk of melanoma increased significantly as height category increased.19 A more 
recent U.S.-based study looking at all keratinocyte cancers and melanoma suggested 
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similar results but used a very small cohort.22 
While height is not a modifiable risk factor, it is one of the elements of BMI. The 
relationship between BMI and melanoma is difficult to explain as it does not follow a 
predictable pattern. This study aims to evaluate how melanoma risk may be influenced by 
height independent of BMI in a U.S. cohort with control for UV exposure.  
4.3 Methods 
4.3.1 PLCO Methods 
The PLCO is a randomized trial developed to evaluate the effect of screening for 
prostate, lung, colorectal, and ovarian cancers on site-specific cancer mortality. The trial 
included 10 screening centers across the US and enrolled 78,216 women and 76,685 men 
between the ages of 55 and 74. Participants were excluded if they were currently 
undergoing treatment for cancer or had been previously diagnosed with one of the four 
cancers being studied, had surgical removal of colon, lung, or prostate, were on another 
cancer screening/prevention trial, or had colonoscopy, sigmoidoscopy, or barium enema 
in the 3 years prior to enrolling. Each participant completed a baseline questionnaire and 
dietary questionnaire. Those in the control arm received standard of care and were 
followed for 13 years. Enrollment took place at the 10 study centers from 1993 until 
2001. Additional details on the methods of this trial were published previously.26  
The current study employed a secondary data analysis of the PLCO data. These 
data were obtained and analyzed using Stata/IC 14.1.51 Of the 154,897 PLCO 
participants, 141,866 were included in this study (see Figure 4.1).  
Descriptive statistics were used to define the variables of interest for this study. 
Age in years was divided into 4 categories (55-59, 60-64, 65-69, 70-78). Because there 
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were so few non-White PLCO participants who developed melanoma, race was 
categorized into White and non-White categories only. Education categories were divided 
into those who did not finish high school, high school graduates, those who did some 
college or posthigh school education, and college graduates. 
4.3.2 UV Exposure 
UV exposure was based on the average UV measure of the study center where the 
person was enrolled. The average UV index for the last 4 years for each city was used to 
generate an average UV index for that city. These numbers were assessed by the 
Environmental Protection Agency and were reported by www.homefacts.com54 as annual 
averages. For each city, the average of the annual UV index for the years 2011-2015 was 
calculated. High UV index was defined as 5 or greater and low UV index was less than 5 
for the model stratified on UV index.  
4.3.3 Tumor Thickness 
Tumor thickness is recognized as the most accurate prognostic factor in 
melanoma but was not captured in the PLCO Trial. In order to evaluate effects on tumor 
thickness, de-identified pathology reports, if available, were obtained for those 
participants who had melanoma. Of the 1,432 cases of melanoma, 520 had available 
pathology reports. These were individually reviewed to record tumor thickness, which 
was available in 473 cases.  
4.3.4 Body Mass Index  
BMI was reported by study participants as they enrolled in the PLCO trial. They 
were asked to recall their weight at age 20 and age 50. Weight and height at study entry 
was also recorded. BMI categories are the standard BMI categories: below 18.5 
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(underweight), 18.5-24.9 (normal), 25-29.9 (overweight), and above 30 (obese). Weight 
change was also calculated as a percentage by calculating the difference between weight 
at age 20 and weight at age 50 and then dividing by weight at age 20. 
4.3.5 Height  
Height was reported as a continuous variable in inches. The cohort was divided 
first by sex and then into quartiles by height. Table 4.1 shows a breakdown of the ranges 
of height by sex and quartile. According to the CDC, the average height of U.S. adult 
men is 69.3 inches and adult women is 63.8 inches.81 The PLCO cohort was slightly taller 
on average (69.9 inches in men and 64.2 inches in women).  
4.4 Statistical Analysis 
Two-sample t tests and chi-square analysis were used to evaluate the difference in 
melanoma rates between men and women, White and non-White, different age groups, 
study centers, and categories of height. A Cox proportional-hazards model was used to 
estimate the risk of melanoma based on height. In this model, univariate analysis was 
used for crude HRs and multivariate analysis included variables that may influence height 
and risk of melanoma. These factors are sex, age, average UV at study center, and race. 
Univariate and multivariate linear regression were used to evaluate the relationship 
between height and melanoma. 
4.5 Results 
Table 4.2 shows the characteristics of the PLCO cohort participants who 
developed melanoma compared to the PLCO participants who did not. Participants who 
developed melanoma were slightly older (mean age at study entry 63 years) compared to 
those who did not (mean age at study entry 62.6 years). Of participants who developed 
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melanoma, more were male than female (62.8% compared to 37.2%, p < .001). 
Melanomas were nearly all seen in white participants (n = 1,295; 99.0%) with only 13 
(1.0%) cases developing in other races (p < .001). Height in men ranged from 49 to 84 
inches and from 48 to 78 inches in women (Table 4.1). When divided into quartiles, 
proportionately more melanomas were seen in the taller two quartiles (Table 4.2).  
In univariate analysis (Table 4.3), all quartiles of height had an increased risk of 
melanoma when compared to the lowest quartile. When stratified on sex, this held true in 
all except the second quartile in women. In general and when stratified on sex, there was 
a significant trend for increasing risk of melanoma with increasing height (p < .001). 
These significant trends persisted in multivariate analysis (p for trend in all < .001, p for 
trend in men = .037, and p for trend in women = .003). In each case (all, men, and 
women), the tallest quartile had a significantly increased risk of melanoma compared to 
the shortest. This was most pronounced in women with the tallest quartile having a HR of 
1.46 (95% CI 1.09, 1.96; p = .012) compared to the lowest quartile. 
The effect of height on melanoma tumor thickness was evaluated in univariate and 
multivariate linear regression and not found to be predictive (Table 4.4). With the 
exception of race, no variable had a significant impact on tumor thickness. Melanomas in 
non-Whites were more than 3 mm thicker than in Whites (coefficient = 3.28, 95% CI 
2.06, 4.50; p < .001).  
4.6 Discussion 
Previous studies suggested a connection between height and risk of multiple 
cancers. The majority of those did not focus on melanoma and did not control for UV 
exposure. This study supports the association between height and risk of melanoma and 
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attempts to control for UV exposure. It further evaluates the difference between sexes 
when it comes to height and melanoma. 
Overall, two things seem apparent from this study. First, there is a trend of an 
increased risk of melanoma with increasing height. This was seen in the entire cohort and 
persisted when evaluating men and women separately. Second, there is a significantly 
increased risk of melanoma in the tallest quadrant of height. While height increases risk 
of melanoma, it does not seem to influence severity of disease (tumor thickness). 
As mentioned, one of the largest studies on this topic showed similar increased 
risk of melanoma among the highest quintile relative to the lowest in men and women.19 
Similar controls were included for UV exposure based on geographic region. Thune’s 
study was based on a Norwegian population and therefore may have had less geographic 
diversity. It is also worth noting that there were over a million people in that study and 
roughly 5000 melanomas. Our study was smaller but had a higher rate of melanoma (3 
per 1000 in Norway vs 9 per 1000 in the PLCO). In the Norwegian cohort, a relative risk 
of 1.60 was seen in the highest quintile of men and 1.59 in the highest quintile of women. 
A trend of increasing risk with height was also observed. In this study, a HR of 1.31 
(95%CI 1.04, 1.65) was seen in men in and 1.46 (95%CI 1.09, 1.96) in women. The 
Norwegian cohort showed nearly identical increases in risk between men and women 
while this study showed a possible difference between risk in men and women.   
When comparing previously published studies to the findings of this study, it 
seems clear that there is a relationship between melanoma risk and height. While there 
are similarities between study findings, the subtle differences may be reflective of 
differences in population make up and geographic diversity. Furthermore, it is likely that 
there are different risk factors or modifiers between men and women. These might 
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include differing behaviors and social norms that might influence UV exposure and 
biologic differences including hormones among others. The basic biology behind cancer 
is a study of control over cell division or a lack thereof. Processes that stimulate increased 
growth must also rely on the pathways that speed up cell division. It seems logical that 
exposure to carcinogenic entities while an individual is in a phase of increased cell 
division would result in increased risk of cancer. 
Hormones that play a role in height include testosterone, thyroid hormones, and 
human growth hormones. Testosterone has been long studied for its effect on 
melanocytes. While it may not increase melanocyte numbers,82 it may influence the 
melanocyte function.83 While thyroid hormone may influence vitamin D synthesis and 
other skin processes,84 it does not have a proven direct effect on melanocytes. Growth 
hormone has shown to have some influence on melanoma cell lines.25 It has also been 
suggested that the growth hormone receptors may be important in melanoma 
pathogenesis.85 While each of these hormones may play a part in the relationship between 
melanoma risk and height, growth hormone appears to be the most promising prospect for 
exploration. 
The strengths of this study include the number of participants in the PLCO, their 
geographic diversity, and duration of time they were followed. In addition, this is among 
the largest U.S. cohorts to be evaluated for risk of melanoma by height. Weaknesses 
include the fact that the cohort was not developed with melanoma as an original focus. As 
such, more detailed pathologic and staging information about those participants who 
developed melanoma was not available. As noted in most studies of melanoma, the lack 




The relationship between height and all cancer risk has been documented but 
biologically is not well understood. It is not surprising then that a similar risk between 
height and melanoma exists. While height may be the underlying risk factor in the 
relationship between body mass index and melanoma, it also raises questions about the 
biology that leads to growth and how it might impact the skins susceptibility to UV 
radiation. Because increasing height correlates with increased melanoma risk and 
increasing BMI does not, it may be assumed that body surface area is not a contributing 
risk factor for melanoma. The magnitude of the risk increase associated with height 
seems to vary by geography and race as would be expected but may be used to look at 
biologic differences as well where race and geography have innate biological differences. 
A differing risk based on biologic differences between men and women is something that 
warrants further inspection.  
Finally, while height is not a modifiable risk factor, a further investigation of the 
biologic reason for this may support behavior modifications to reduce risk. Even without 
specific proof that the biology behind height is important in carcinogenesis, it seems 
worthwhile to add this to the cadre of reasons why we should teach appropriate sun 




Figure 4.1. CONSORT Diagram for Height and Melanoma.
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Table 4.1. Height in Inches by Quartile and Sex 
Quartile 
 Male  Female 
 n Height  n Height 
       
1  20,861 49–68  18,095 48–62 
2  20,410 69–70  21,230 63–64 
3  18,249 71–72  18,768 65–66 
4  11,888 73–84  12,365 67–78 
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Table 4.2. Comparison of Participants Who Developed Melanoma to Those Who Did 
Not  
Characteristic  Melanoma  No melanoma  p 
         
Average age (in years)  1,308 63.0  140,558 62.6  .001 
         
  n %  n %   
Categories by age (in years)         
<60  385 29.4  47,030 33.5   
60–64  399 30.5  43.397 30.9   
65–69  340 26.0  31,561 22.5   
≥70  184 14.1  18,570 13.2  .004 
         
Sex         
Male  822 62.8  70,586 50.2   
Female  486 37.2  69,972 49.8  <.001 
         
Race         
White  1,295 99.0  124,020 88.2   
Other  13 1.0  16,538 11.8  <.001 
         
Height (quartile)         
1  284 21.7  38,672 27.5   
2  370 28.3  41,270 29.4   
3  367 28.1  36,650 26.1   
4  287 21.9  23,966 17.1  <.001 
         
a Two-tailed t test 
 
b Chi-square test   
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Table 4.3. Height and Risk of Melanoma  
Quartile of height 
Crude hazard ratio  
(95% CI) p 
Multivariate hazard 
ratio (95% CI)a p 
     
All      
1 1.00  1.00  
2 1.21 (1.04, 1.42) .014 1.06 (0.91, 1.25) .439 
3 1.36 (1.17, 1.59) <.001 1.17 (0.99, 1.37) .066 
4 1.64 (1.39, 1.93) <.001 1.37 (1.14, 1.65) .001 
p trend  <.001  <.001 
     
Male onlyb     
1 1.00  1.00  
2 1.29 (1.07, 1.56) .009 1.08 (0.89, 1.32) .432 
3 1.34 (1.10, 1.63) .003 1.09 (0.89, 1.34) .415 
4 1.66 (1.35, 2.04) <.001 1.31 (1.04, 1.65) .023 
p trend  <.001  .037 
     
Female onlyb     
1 1.00  1.00  
2 1.15 (0.89, 1.50 .292 1.03 (0.79, 1.34) .839 
3 1.47 (1.14, 1.90) .003 1.28 (0.98, 1.67) .068 
4 1.70 (1.29, 2.23) <.001 1.46 (1.09, 1.96) .012 
p trend  <.001  .003 
     
a  Controlling for age at enrollment, sex, race, weight age 20, and study center UV 
 
b  Controlling for age at enrollment, race, weight age 20, and study center UV 
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Table 4.4. Multivariate Linear Regression of Melanoma Tumor Thickness, Height, 
Age, Sex, Weight at Age 20, and Study Center 
Breslow depth in mm  




(95% CI) p  
Multivariate  
(95% CI)a p 
       
Height (quartiles)       
1  ref —  ref — 
2  0.16 (-0.14, 0.47) .304  0.16 (-0.15, 0.47) .319 
3  -0.04 (-0.36, 0.28) .803  -0.01 (-0.33, 0.32) .951 
4  0.15 (-0.18, 0.49) .366  0.14 (-0.22, 0.50) .445 
       
Age  0.01 (-0.01, 0.03) .331  0.00 (-0.02, 0.03) .658 
       
Sex       
Male  ref —  ref — 
Female  -0.09 (-0.33, 0.15) 0.462  0.01 (-0.31, 0.33) 0.965 
       
Weight at age 20  0.00 (-0.01, 0.01) 0.215  0.00 (-0.01, 0.01) .290 
       
Race       
White  ref —  ref — 
Non-White  3.32 (2.14, 4.51) <.001  3.28 (2.06, 4.50) <.001 
       
Study center UV       
Low  ref —  ref — 
High  0.20 (-0.04, 0.44) .107  0.10 (-0.14, 0.34) .425 
       
a Multivariate linear regression including all variables in this table 











The search for additional risk factors of melanoma is necessary as not all cases are 
attributable to UV exposure. UV attributable melanoma estimates range from 65% to 
more than 90%. 86,87 In addition, the rate of disease may be lower in non-White 
populations1 but the disease severity in this population appears to be worse.  
It is possible that practitioners may not have melanoma high on their clinical radar 
when evaluating patients with darker skin tones leading to a delay in diagnosis. It is also 
likely that people with lower innate risk (darker skin) have less concern for skin lesions, 
again, leading to a delay in diagnosis. Regardless, it is important to understand why 
melanoma is more severe in non-White races. In all three studies, the only factors that 
influence tumor thickness were race and education. These data show a clear health 
disparity.  
Other factors are likely at play in addition to delayed diagnosis in this context. 
Vitamin D levels are low in a large majority of ethnic minorities. This study contributes 
additional understanding to the vitamin D question. Understanding that women in the 
highest quartile of vitamin D intake have a lower risk of invasive melanoma could guide 
education efforts. Additionally, our study is novel in that it shows a weak but statistically 




The potential that BMI at age 20 potentially has an opposite effect on risk in men 
compared to women (namely a potential protective effect in men who are underweight 
and women who are overweight) adds a new vein of questioning to the current melanoma 
literature. Behaviors influenced by BMI as well as sex-specific hormones should be 
evaluated for potential risk modifiers. 
Finally, the striking linear relationship between height and melanoma risk and the 
presumption that the majority of risk is accumulated in the form of UV at a younger age 
raises multiple unanswered questions. This may identify that the melanocytes are indeed 
more susceptible to UV damage during the formative teen and young adult year. Growth 
hormone and other hormones related to height should be evaluated. One way to evaluate 
this is in a case-control setting following people who have used growth hormone 
replacement therapy compared to their peers who were the same height and age when the 
therapy was started. Regardless of methods, this relationship should be explored further. 
This research benefited from a number of strengths. Most importantly, the data 
supplied by the PLCO represent a longitudinal database that is among the largest for 
evaluating melanoma risk factors in the US. Prospectively collected information on each 
participant including extensive food and diet information allowed us to evaluate dietary 
risk factors with confidence. Likewise, prospectively collected serum provided serum 
vitamin D levels on a subset of participants and evaluation of the relationship between 
serum vitamin D levels and estimates of intake based on self-reported surveys. Finally, 
with 10 different centers of enrollment, an objective proxy measure for UV exposure was 
available.  
The limitations of this research include inconsistent reporting of melanoma 
characteristics, an issue inherent to the lack of uniform reporting criteria across 
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pathologists. Ideally, serum vitamin D levels would have been assessed on all individuals 
to more exactly solidify the relationship between vitamin D levels and melanoma in a 
larger group and further evaluate the relationship between self-reported measures and 
actual serum levels. The PLCO incorporated a broad swath of the U.S. population 
geographically but did not include participants younger than 55. While the majority of 
melanomas are seen in older individuals, including younger participants might have 
shown a different relationship stratified on age. Lastly, the inability to adequately control 
for individual UV exposure remains a limitation. 
Any future study needs to consider and, if possible, compensate for the complex 
nature of the confounding influence of UV exposure. The best method to control for this 
is to measure UV exposure for each individual over a period of time, however, this is 
nearly impossible to measure so estimates must be performed. Having participants wear a 
UV dosimeter that can be worn similar to a wrist watch is ideal but is limited by cost due 
to the amount of monitoring that would need to be done. The mutations that result in 
melanoma are usually the result of decades of UV exposure making a time-limited UV 
measurement less exact. In addition, behaviors (and thus UV exposures) may change over 
the course of aging. Taking a small measure of UV exposure at one point and 
extrapolating over time is therefore problematic. In addition, people may not stay in the 
same area for long periods of time so mobility must be accounted for as latitude and 
elevation influence UV exposure. Taking into account the need for large population-
based studies, this becomes even less attainable. Depending on funding and study aims, 
the best solution may be to track UV indexes and account for amount of time spent 
outdoors by each participant. 
While the primary aims of this research focused on the incidence of melanoma, 
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the striking disparity in severity of melanoma between races is important. Future research 
might focus on those groups with more severe disease at onset. The most obvious 
approach would be to identify the reasons the increased severity exists (most likely a 
delay in diagnosis) and do root cause analyses. This can then lead to population-based 
interventions with health care providers and the higher risk groups. 
By looking at both height and BMI, the important aspects of body size and shape 
become more apparent. The apparent explanation that height is more indicative of 
melanoma risk does not completely explain why some categories of BMI at age 20 had a 
protective effect. Body size and shape as it relates to body image has been a hot topic. 
Body image is self-perceived in the context of our cultural norms and cues. The fact that 
BMI has some influence on melanoma risk, should cause us to question how body image 















Table A.1. Mean Serum Vitamin D Levels by Study Center 
 n 
Serum D Average UV 
index M Range 
      
Pacific 149 30.3 9.8 54.3 9.5 
Colorado 591 25.2 6.7 70.7 6.1 
Utah 698 25.0 5.5 75.5 5.8 
Minnesota 1,416 24.7 2.5 89.4 3.9 
Marshfield 916 24.5 3.0 61.1 3.9 
Georgetown 419 24.2 3.2 62.5 4.8 
Alabama 223 24.1 6.7 51.1 6.1 
St. Louis 666 24.0 2.5 72.8 4.9 
Pittsburgh 861 23.8 3.4 63.5 4.3 
Henry Ford 759 22.9 4.1 59.1 4.1 
      




Table A.2. Regression of Serum Vitamin D (ng/ml) by Quadrant of Vitamin D Intake 
Vitamin D intake Coefficient (95% CI) p 
   
Low ref — 
Med 1.61 (0.98, 2.25) <.001 
High 2.93 (2.28, 3.57) <.001 
Very high 3.94 (3.30, 4.58) <.001 
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Table A.3. Range of Total Vitamin D Intake by Quartile 
Quartile n M Range 
    
1 27,712 2.31 0.00 3.86 
2 27,624 6.64 3.86 10.73 
3 27,684 12.18 10.74 13.50 
4 27,656 16.31 13.50 169.83 
     
Note. NIH recommends 15 mcg/day in adults age 51-70 and 20 mcg/day in adults >70. 
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Table A.4. Demographic Comparison of Participants Who Developed Melanoma With 
a Pathology Report Available Compared to Those Who Developed 





n (%) p  
    
Sex    
Men 321 (40.4) 474 (59.6) 
 
Women 166 (31.9) 354 (68.1) .002 (Chi2) 
    
Average age in years 69.5 70.6 .004 
    
Education 
   
No high school 13 (2.5) 31 (3.9) 
 
High school 76 (14.6) 126 (15.9) 
 
Some college 157 (30.3) 248 (31.3) 
 
College grad 273 (52.6) 387 (48.9) .367 (Chi2) 
    
Race 
   
White 515 (99.0) 787 (99.0) 
 
Other 5 (1.0) 8 (1.0) .936 (Chi2) 
    
Dietary D intake avg 9.8 10 .557 
    
Serum D average 25.9 25.9 .987 
    
BMI 
   
Under 21 (4.1) 45 (5.8) 
 
Normal 404 (78.5) 633 (81.0) 
 
Over 81 (15.7) 90 (11.5) 
 
Obese 9 (1.7) 14 (1.8) .104 (Chi2) 
    
Height (in inches avg) 68.6 68.2 .0843 
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Table A.5. Demographic Comparison of PLCO Participants Who Had Serum Vitamin 
D Levels Available Compared to Those Who Did Not 
  Has serum D No serum D   
    
Sex    
Men 3,472(4.8%) 68643(95.2%) 
 
Women 3,264(4.6%) 67657(95.4%) p = .058 (Chi2) 
    
Avg age 75.5 74 p < .001 
    
Education 
   
No high school 494(7.3%) 10080(7.4%) 
 
High school 1512(22.5%) 31277(23.0%) 
 
Some college 2274(33.8%) 46727(34.4%) 
 
College grad 2449(37.0%) 47849(35.2%) p = .253 (Chi2) 
    
Race 
   
White 6291(93.4%) 119969(88.0%) 
 
Other 445(6.6%) 16331(12.0%) p < .001 (Chi2) 
    
Dietary D intake avg 9.35 9.36 p = .939 
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